Last mentioned: Feb 24, 2026
Root and Catalyst Pharmaceuticals are scheduled to report quarterly results on Wednesday, offering investors a dual look at high-growth technology and healthcare resilience. Both companies face critical tests regarding their respective expansion strategies and bottom-line improvements in a shifting macroeconomic environment.
Catalyst Pharmaceuticals (CPRX) and Root (ROOT) are scheduled to release their quarterly financial results this Wednesday, February 25. For Catalyst, the report will be a critical barometer for the commercial uptake of its newly launched DMD treatment, Agamree, and the continued stability of its flagship LEMS therapy, Firdapse.
Root and Catalyst Pharmaceuticals are scheduled to release their quarterly financial results this Wednesday, providing critical data points for the insurtech and orphan drug sectors. Investors are looking for Root's progress toward profitability and Catalyst's continued dominance in the LEMS market.